Seer, Inc. (SEER) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Seer, Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Overview: Seer is a life sciences technology company developing the Proteograph Product Suite, a platform for unbiased, deep, and large-scale proteomics. The suite includes consumable assays (Proteograph ONE), an automation instrument (SP200), and data analysis software. The company targets academic, biopharmaceutical, and clinical research markets to enable population-scale studies and AI-driven biological discovery.
Key Milestone: In May 2025, Seer launched the Proteograph ONE assay and SP200 instrument, achieving approximately a 10-fold improvement in throughput compared to the first-generation assay, enabling the processing of over 1,000 samples per week.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Total Revenue | $16,578 | $14,170 |
| Gross Profit | $8,465 | $7,055 |
| Gross Margin | 51.1% | 49.8% |
| Net Loss | $(73,600) | $(86,599) |
| Operating Loss | $(77,992) | $(100,101) |
| Cash Used in Operating Activities | $(44,448) | $(46,109) |
| Cash, Cash Equivalents & Investments | $240,600 | $236,410 |
| Accumulated Deficit | $(465,972) | $(392,372) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 17% to $16.6 million, driven by a 29% increase in product revenue and a 40% increase in service revenue. Related party revenue decreased 67% to $0.8 million.
- Expense Reduction: Operating expenses decreased 19% to $86.5 million. Research and Development (R&D) expenses fell 13% to $43.9 million, and Selling, General, and Administrative (SG&A) expenses dropped 25% to $42.6 million. These reductions were primarily due to lower stock-based compensation ($15.4 million in 2025 vs. $28.2 million in 2024) and reduced professional services.
- Net Loss Improvement: Net loss narrowed by 15% to $73.6 million, reflecting the reduction in operating expenses despite lower interest income ($11.5 million in 2025 vs. $16.7 million in 2024).
- Capital Structure: The company repurchased approximately 5.3 million shares of Class A common stock for $10.2 million under its share repurchase program. On December 9, 2025, all outstanding Class B common stock was automatically converted to Class A common stock.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant losses and negative cash flows from operations for the foreseeable future as it invests in commercialization, R&D, and infrastructure. The company believes its current cash and investments ($240.6 million) are sufficient to fund operations for at least the next 12 months.
Strategic Focus:
- Expanding the installed base of Proteograph instruments and driving consumable utilization.
- Winning population-scale cohort programs (e.g., collaborations with Korea University and Discovery Life Sciences).
- Establishing leadership as a data platform for AI-driven biology.
Key Risks:
- Profitability: History of net losses and uncertainty regarding the ability to achieve or sustain profitability.
- Market Acceptance: Success depends on broad scientific and market adoption of the Proteograph Product Suite, which is a new technology.
- Regulatory: Products are currently labeled "Research Use Only" (RUO). Future expansion into clinical diagnostics would require FDA clearance/approval, which is costly and uncertain.
- Intellectual Property: Reliance on licensed patents from Brigham and Women's Hospital (BWH) and potential challenges to patent validity (e.g., Inter Partes Review proceedings).
- Supply Chain: Dependence on a single contract manufacturer (Hamilton Company) for automation instruments.
Investor Verification Checklist
- Revenue Concentration: Verify the sustainability of revenue growth given that related party revenue (PrognomiQ) dropped significantly from 17% of total revenue in 2024 to 5% in 2025.
- Stock-Based Compensation: Assess the impact of the significant reduction in stock-based compensation ($12.8 million decrease) on future expense trends as vesting schedules change.
- Liquidity Runway: Confirm the $240.6 million cash position against the projected burn rate of ~$44 million annually to validate the 12-month liquidity assertion.
- Installed Base Growth: Monitor the expansion of the installed base (reported as >65% growth in 2025) and the resulting "pull-through" of consumable sales.
- Patent Status: Review the status of the Inter Partes Review (IPR) proceedings challenging the validity of key patents licensed from BWH.